Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Pediatrix Acquires Atopic Dermatitis Therapy in $96 Million Agreement

publication date: Nov 30, 2022

Shanghai Pediatrix Therapeutics in-licensed greater China rights to an immuno-inflammatory disease candidate from Pennsylvania’s Aclaris in a $96 million deal. Aclaris’s ATI-1777 is a “soft” Janus kinase 1/3 inhibitor that aims to lower systemic exposure to the drug. Pediatrix will own commercialization and manufacturing rights for any disease, including atopic dermatitis and for any age group. Pediatrix has a portfolio of more than 10 products for dermatology, neurology, neonatology, allergy and immunology indications. More details....

Stock Symbol: (NSDQ: ACRS)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital